CXCR4 and Miyoshi myopathy: Thus, as a proof-of-concept, the first clinical application of [68Ga]Pentixafor for CXCR4-directed PET imaging has been carried out in patients with lymphoproliferative diseases, i.e., NHL and MM [85].